Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE:002294)

China flag China · Delayed Price · Currency is CNY
53.61
-1.30 (-2.37%)
Oct 23, 2025, 10:45 AM CST
-2.37%
Market Cap61.21B
Revenue (ttm)4.10B
Net Income (ttm)622.56M
Shares Out1.11B
EPS (ttm)0.56
PE Ratio98.10
Forward PE90.02
Dividend0.50 (0.89%)
Ex-Dividend DateMay 14, 2025
Volume1,908,233
Average Volume8,922,429
Open56.41
Previous Close54.91
Day's Range53.58 - 56.41
52-Week Range27.66 - 65.63
Beta0.52
RSI51.92
Earnings DateOct 24, 2025

About SHE:002294

Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of medicines and medical devices in China. The company offers drugs for various therapeutic fields, such as thrombosis, hypertension and related diseases, osteoporosis, and infections, as well as anti-osteolysis, antiallergic, antiepileptic, and antidepressant medicines. It also develops Sacubitril Allisartan Calcium, Allisartan Isoproxil Amlodipine Besylate Tablets, and Allisartan IsoproxilIndapamide Sustained-release Tablets, which are in ph... [Read more]

Sector Healthcare
Founded 1998
Employees 3,596
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 002294
Full Company Profile

Financial Performance

In 2024, SHE:002294's revenue was 4.01 billion, an increase of 19.22% compared to the previous year's 3.37 billion. Earnings were 601.57 million, an increase of 3.71%.

Financial Statements

News

There is no news available yet.